Actions

Newsfeed Popular Local Discover Follows Blocks Bookmarks Filters Settings PowerUps Help Updates

seekingalpha.com / Share Newsitem

View, share or embed this newsitem using the details below.

Seeking Alpha | Stock Market Analysis & Tools for Investors

$$@seekingalpha.com/3 hours3h

Blueprint Medicines beats Q3 top and bottom-line estimates

Blueprint Medicines reported strong Q3 2024 results with a GAAP EPS beat of $0.08 and revenue beating by $0.71M, showing significant growth year-over-year.

https://newsreadery.com/go/c56e0fab7ac0a5fde25e5f1553c26bd0

Save

Back

Read Full Article